KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Assets (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Current Assets readings, the most recent being $462.6 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 36.86% to $462.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $462.6 million, a 36.86% increase, with the full-year FY2025 number at $462.6 million, up 36.86% from a year prior.
  • Current Assets hit $462.6 million in Q4 2025 for Esperion Therapeutics, up from $360.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $462.6 million in Q4 2025 to a low of $170.7 million in Q3 2021.
  • Median Current Assets over the past 5 years was $283.0 million (2021), compared with a mean of $292.1 million.
  • Biggest five-year swings in Current Assets: fell 29.71% in 2021 and later skyrocketed 68.1% in 2024.
  • Esperion Therapeutics' Current Assets stood at $329.0 million in 2021, then fell by 25.01% to $246.7 million in 2022, then decreased by 18.49% to $201.1 million in 2023, then skyrocketed by 68.1% to $338.0 million in 2024, then skyrocketed by 36.86% to $462.6 million in 2025.
  • The last three reported values for Current Assets were $462.6 million (Q4 2025), $360.5 million (Q3 2025), and $342.6 million (Q2 2025) per Business Quant data.